{"id":"promitil","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT03823989","NCT06478862","NCT04729205","NCT01705002"],"aliases":["Pegylated Liposomal Mitomycin-C Lipid-based Prodrug","Folfox"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Promitil","companyId":"lipomedix-pharmaceuticals-inc","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Lipomedix Pharmaceuticals Inc.","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Promitil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03823989","phase":"Phase 1","title":"An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Canc","status":"COMPLETED","sponsor":"Lipomedix Pharmaceuticals Inc.","isPivotal":false,"enrollment":18,"indication":"Cancer, Solid Tumor","completionDate":"2021-12-30"},{"nctId":"NCT06478862","phase":"Phase 2","title":"A Phase 2A Multicenter, Open Label Study of Promitil for the Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After First Line Therapy","status":"TERMINATED","sponsor":"Lipomedix Pharmaceuticals Inc.","isPivotal":false,"enrollment":19,"indication":"Cancer of Ovary, Pancreatic Ductal Adenocarcinoma","completionDate":"2026-01-02"},{"nctId":"NCT04729205","phase":"Phase 1","title":"An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies","status":"TERMINATED","sponsor":"Lipomedix Pharmaceuticals Inc.","isPivotal":false,"enrollment":9,"indication":"Cancer, Gastro-Intestinal Intraepithelial Neoplasia","completionDate":"2023-09-12"},{"nctId":"NCT01705002","phase":"Phase 1","title":"A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.","status":"COMPLETED","sponsor":"Lipomedix Pharmaceuticals Inc.","isPivotal":false,"enrollment":88,"indication":"Cancer, Solid Tumor","completionDate":"2018-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":35,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}